FLT3
Cluster of differentiation antigen 135; CD135; Fms like tyrosine kinase 3
FLT3 (Fms-like tyrosine kinase 3, CD135) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. FLT3 is the receptor for the cytokine Flt3 ligand (FLT3L). FLT-3 is expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. The FLT3 gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). Besides, high levels of wild-type FLT3 have been reported for blast cells of some AML patients without FLT3 mutations. These high levels may be associated with worse prognosis. Signaling through FLT3 plays a role in cell survival, proliferation, and differentiation. FLT3 is important for lymphocyte (B cell and T cell) development, but not for the development of other blood cells. Two cytokines that down modulate FLT3 activity are TNF-Alpha and TGF-Beta.
All Product Categories
-
FLT3 Inhibitors
(308)
View all products
-
FLT3 Antagonist
(1)
View all products
-
FLT3 Modulator
(1)
View all products
-
FLT3 Degraders
(12)
View all products
-
FLT3 Control
(1)
View all products
-
FLT3 Substrate
(1)
View all products
-
FLT3 Ligands
(6)
View all products
-
Flt-3/CD135 Proteins
(11)
View all products
-
FLT3 Related Products (336)
Related Products (336)
-
Recombinant Proteins (11)
-
K783-0308
0 ImagesCat. No.: HY-115906CAS No.: 422554-29-8K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC50 values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC50=10.5 µM) and MV-4-11 (IC50=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase.
-
FLT3-IN-12
0 ImagesCat. No.: HY-143895CAS No.: 2499966-67-3FLT3-IN-12 is a potent, selective and orally active FLT3 kinase inhibitor with IC50s of 1.48 nM and 2.87 nM for FLT3-WT and FLT3-D835Y, respectively. FLT3-IN-12 possesses high selectivity over c-KIT (>1000-fold). FLT3-IN-12 has an excellent anti-AML (acute myeloid leukemia) activity (MV4-11, IC50 of 0.75 nM).
-
FLT3-ITD-IN-3
0 ImagesCat. No.: HY-173214CAS No.: 3018150-80-3FLT3-ITD-IN-3 (13v), an orally active FLT3-ITD (FLT3 internal tandem duplication) inhibitor, disrupts FLT3 signal transduction and induced G0/G1 cell cycle arrest and apoptosis. FLT3-ITD-IN-3 (13v) is used in the research of acute myeloid leukemia (AML).
-
FLT3-IN-15
0 ImagesCat. No.: HY-146886CAS No.: 2435562-99-3FLT3-IN-15 is a highly potent and orally active FLT3 inhibitor with IC50s of 0.87 nM and 0.32 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-15 can be used for researching acute myeloid leukemia.
-
SR-2890
0 ImagesCat. No.: HY-123859CAS No.: 1454584-91-8SR-2890 is a highly selective, ATP-competitive inhibitor of casein kinase CK1δ and CK1ε, with IC50 values of 4 nM and 44 nM, respectively, and a Ki of 14 nM for CK1δ. SR-2890 exhibits antiproliferative effects. SR-2890 blocks the serine/threonine kinase activity of CK1δ and weakly inhibits a few off-target kinases such as FLT3, CDK4. SR-2890 has an oral bioavailability of 10% and a blood-brain barrier penetration rate of <1%. SR-2890 demonstrates stable in vitro metabolism and favorable in vivo pharmacokinetic properties, effectively inhibiting the growth of human A375 melanoma cells. SR-2890 can be used in melanoma research and is also a useful compound for studying CK1δ/ε-related diseases such as Alzheimer's disease.
-
3-Hydroxy Midostaurin-d5
0 ImagesCat. No.: HY-108263SSynonyms: CGP52421-d53-Hydroxy Midostaurin-d5 is a deuterium labeled 3-Hydroxy Midostaurin. 3-Hydroxy Midostaurin is a metabolite of PKC412, which effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively.
-
HPK1-IN-2 TFA
0 ImagesCat. No.: HY-132150CPurity: 99.56%
-
YTB53
0 ImagesCat. No.: HY-184431YTB53 is a MNK1 and MNK2 inhibitor with IC50s of 37 nM and 9 nM, respectively. YTB53 inhibits PDGFRα, TRKB and FLT3 in leukemia cells. YTB53 induces cell cycle arrest, apoptosis, pyroptosis, and mitochondrial dysfunction. YTB53 exhibits antiangiogenic effects. YTB53 can be used for the study of acute myeloid leukemia (AML).
-
FLT3/IRAK4-IN-1
0 ImagesCat. No.: HY-176735FLT3/IRAK4-IN-1 is a selective FLT3/IRAK4 inhibitor with the remarkable activity towards FLT3-WT (IC50 = 1.95 nM), FLT3-D835Y (IC50 = 3.22 nM) and IRAK4 (IC50 = 53.72 nM). LT3/IRAK4-IN-1 has relatively low toxicity to normal bone marrow cells, can effectively promote cell apoptosis, and has the potential to overcome drug resistance. FLT3/IRAK4-IN-1 can be used for research on acute myeloid leukemia (AML).
-
BTK-IN-48
0 ImagesCat. No.: HY-182293CAS No.: 3114078-55-3
-
FLT3-IN-33
0 ImagesCat. No.: HY-174911CAS No.: 3035801-67-0FLT3-IN-33 (Compound 7r) is a FLT3 inhibitor with an IC50 of 7.82 nM. FLT3-IN-33 has superior anticancer activities against acute myeloid leukemia (AML) cells, such as MV4-11 and MOLM-13 cells. FLT3-IN-33 significantly induces cell apoptosis and inhibits phosphorylation of FLT3 pathways. FLT3-IN-33 can be used for AML and other cancers research.
-
FLT3-IN-23
0 ImagesCat. No.: HY-156410CAS No.: 2489528-97-2FLT3-IN-23 (compound 15) is an inhibitor of JFMS-like tyrosine kinase 3 (FLT3) with an IC50 of 7.42 nM. FLT3-IN-23 has antiproliferative activities against BaF3 cells carrying various FLT3-TKD and FLT3-ITD-TKD mutations.
-
FLT3/JAK2/BRD4 ligand-1
0 ImagesCat. No.: HY-175611CAS No.: 3067695-60-4
-
LY2457546
0 ImagesCat. No.: HY-107144CAS No.: 908265-94-1LY2457546 is a potent and orally active multi-targeted anti-angiogenic tyrosine kinases inhibitor. LY2457546 demonstrates potent activity against targets that include VEGFR2, PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. LY2457546 can be used for the research of cancer, such as leukemia.
-
JI6
0 ImagesCat. No.: HY-18949CAS No.: 856436-16-3JI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ～40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC50s of ～250 and ～500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia.
-
FLT3-IN-32 hydrochloride
0 ImagesCat. No.: HY-174437BCAS No.: 3047195-66-1FLT3-IN-32 hydrochloride is a potent and orally active FLT3 inhibitor with an IC50s of 0.29 nM, 0.77 nM and 2.07 nM against FLT3-ITD, FLT3-D835Y and FLT-N676K. FLT3-IN-32 hydrochloride reduces the phosphorylation of FLT3 and its downstream signaling molecules (STAT5, MAPK, AKT) to induce FLT3-mutated Ba/F3 cells apoptosis. FLT3-IN-32 hydrochloride shows significant anti-tumor efficacy in n the MV4-11 xenograft model. FLT3-IN-32 hydrochloride can be used for the study of acute myeloid leukemia (AML).
-
TRK II-IN-1
0 ImagesCat. No.: HY-151945CAS No.: 2904690-41-9
-
FLT3 ligand-4
0 ImagesCat. No.: HY-175900CAS No.: 3031481-63-4
-
FLT3/D835Y-IN-1
0 ImagesCat. No.: HY-143434CAS No.: 2648799-49-7FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective FLT3 and FLT3/D835Y inhibitor, with IC50 values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia).
